Interim results point to the treatment's safety, but final results on its effectiveness will be received in several months.
Kamada Ltd. (TASE: KMDA) has completed the Phase II effectiveness clinical trial of the aerosolized version of its Alpha-1 Antitrypsin (AAT) protein for the treatment of cystic fibrosis. The results indicate that AAT is safe for use, including by children, but the effectiveness results of the drug have not yet been fully analyzed. Full results are due to be published in 2-3 months.
100,000 people suffer from cystic fibrosis worldwide, and the average lifespan of patients is 30 years. In recent years, various drugs have extended patients' lifespan by decades.
Kamada CEO David Tsur said, "We hope that we too can contribute."
Kamada is carrying out advanced trials for AAT for the treatment of hereditary emphysema and bronchiectasis.
Published by Globes [online], Israel business news - www.globes-online.com - on August 21, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008